Aprotinin and renal risk in cardiac surgery [1]

Transfusion

Volumn 46, Issue 12, 2006, Pages 2207-

  Casati, Valter ^a   Galli, Laura ^b   D'Angelo, Armando ^b  

^a Division of Cardiovascular Anesthesia and Intensive Care   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; CREATININE; TRANEXAMIC ACID;

BLOOD TRANSFUSION; CREATININE BLOOD LEVEL; HEART SURGERY; HUMAN; KIDNEY DISEASE; LETTER; POSTOPERATIVE HEMORRHAGE; THROMBOSIS;

APROTININ; CARDIAC SURGICAL PROCEDURES; HEMOSTATICS; HUMANS; KIDNEY; POSTOPERATIVE COMPLICATIONS; RISK; TRANEXAMIC ACID;

EID: 33751375814     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.01051.x     Document Type: Letter

References (5)

1. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion 2006;46:327-38.
2. Mangano DT, Tudor IC, Dietzel C. for the Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
3. Blackstone EH. Comparing apples and oranges. J Thorac Cardiovasc Surg 2002;123:8-15.
4. Casati V, Guzzon D, Opizzi M, et al. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg 2000;120:520-7.
5. Kincaid EH, Ashburn DA, Hoyle JR, et al. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg 2005;80:1388-93.